natgillin/translations-raw huggingface dataset:
Decision (EU) 2015/422 of the European Parliament and of the Council of 17 December 2014 on the mobilisation of the European Union Solidarity Fund (OJ L 68, 13.3.2015, p. 47).
Zato se bo celotni znesek, ki bo uporabljen, financiral s prerazporeditvijo odobritev, ki so za predplačila na voljo v splošnem proračunu Evropske unije za proračunsko leto 2015, tako da ne bo treba zagotoviti nobenih dodatnih odobritev.
Council Implementing Decision (EU) 2015/1873
Izvedbeni sklep Sveta (EU) 2015/1873
of 8 October 2015
z dne 8. oktobra 2015
on subjecting 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR) and 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) to control measures
o uvedbi nadzornih ukrepov za 4-metil-5-(4-metilfenil)-4,5-dihidrooksazol-2-amin (4,4′-DMAR) in 1-cikloheksil-4-(1,2-difeniletil)piperazin (MT-45)
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances [1], and in particular Article 8(3) thereof,
ob upoštevanju Sklepa Sveta 2005/387/PNZ z dne 10. maja 2005 o izmenjavi podatkov, oceni tveganja in nadzoru nad novimi psihoaktivnimi snovmi [1] ter zlasti člena 8(3) Sklepa,
A Risk Assessment Report on the new psychoactive substance 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR) was drawn up in accordance with Article 6 of Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and was subsequently submitted to the Commission and to the Council on 19 September 2014.
Poročilo o oceni tveganja glede nove psihoaktivne snovi 4-metil-5-(4-metilfenil)-4,5-dihidrooksazol-2-amin (v nadaljnjem besedilu: 4,4′-DMAR) je bilo pripravljeno v skladu s členom 6 Sklepa 2005/387/PNZ na posebnem sestanku razširjenega znanstvenega odbora Evropskega centra za spremljanje drog in zasvojenosti z drogami (ECSDZD) ter je bilo nato Komisiji in Svetu predloženo 19. septembra 2014.
4,4′-DMAR is a synthetic substituted oxazoline derivative.
4,4′-DMAR je sintetični substituirani derivat oksazolina.
It is a derivative of aminorex and 4-methylaminorex (4-MAR), two synthetic stimulants controlled under the 1971 United Nations Convention on Psychotropic Substances.
Je derivat aminoreksa in 4-metilaminoreksa (4-MAR), dveh sintetičnih poživil, nadzorovanih v skladu s Konvencijo Združenih narodov o psihotropnih snoveh iz leta 1971.
Nine Member States have reported detections as a result of seizures of the substance, mainly in the form of white or coloured powders and tablets, as well as biological and collected samples.
4,4′-DMAR se prodaja in uporablja pod lastnim imenom, vendar se lažno prodaja na nezakonitem trgu tudi kot ekstazi in amfetamini.
4,4′-DMAR emerged on the new psychoactive substances market as a ‘research chemical’ sold by internet retailers, and it is now available on the street market.
Ena od držav članic je poročala o primeru zastrupitve brez smrtnega izida.
There have been 31 deaths associated with 4,4′-DMAR registered in three Member States, between June 2013 and June 2014.
Ni podatkov o razširjenosti uporabe 4,4′-DMAR.
In most cases, 4,4′-DMAR was either the cause of death or, together with other substances, is likely to have contributed to death.
Vendar glede na razpoložljive informacije njegova uporaba ni razširjena.
One Member State has reported a case of non-fatal intoxication.
Glede na informacije, pridobljene ob smrtnih primerih, so uporabniki zaužili 4,4′-DMAR tudi nevede, ko so želeli zaužiti druga poživila.
There are no studies on the toxicity of 4,4′-DMAR.
Vpletenost organiziranega kriminala pri proizvodnji, distribuciji in dobavi 4,4′-DMAR ter trgovini z njim znotraj Unije je omejena.
There is no prevalence data on the use of 4,4′-DMAR.
Kemične predhodne sestavine in sintezne poti, ki se uporabljajo pri proizvodnji 4,4′-DMAR, niso znane.
However, the information available suggests that it has not been widely used.
4,4′-DMAR ni na seznamu za nadzor na podlagi Enotne konvencije Združenih narodov o mamilih iz leta 1961 ali Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971.
Information obtained from cases involving death also suggests that users unknowingly consumed 4,4′-DMAR when seeking other stimulants.
Za zdaj ni v postopku ocenjevanja, ocena v okviru sistema Združenih narodov pa ni bila opravljena in tudi ni načrtovana.
There is limited involvement of organised crime in the manufacture, distribution, trafficking and supply of 4,4′-DMAR within the Union.
4,4′-DMAR nima ugotovljene ali priznane medicinske ali veterinarske uporabe v Uniji.
The chemical precursors and the synthetic routes used to manufacture 4,4′-DMAR are unknown.
Ni znakov, da bi se ta snov uporabljala za druge namene, z izjemo uporabe v analitičnih referenčnih materialih in znanstvenih raziskavah, namenjenih proučevanju njenih kemijskih, farmakoloških in toksikoloških lastnosti.
4,4′-DMAR is not listed for control under the 1961 United Nations Single Convention on Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances.
Poročilo o oceni tveganja navaja, da je o 4,4′-DMAR na voljo malo znanstvenih dokazov, ter opozarja na potrebo po nadaljnjih raziskavah, da bi se ugotovila zdravstvena in socialna tveganja, ki jih povzroča ta snov.
It is not currently under assessment, and has not been under assessment, by the United Nations' system, and no such assessment is planned.
Vendar je glede na razpoložljive dokaze in informacije dovolj razlogov za uvedbo nadzornih ukrepov za 4,4′-DMAR po vsej Uniji.
4,4′-DMAR has no established or acknowledged human or veterinary medical use in the Union.
Ker je uživanje 4,4′-DMAR tvegano za zdravje, saj je bila prisotnost te snovi dokumentirana v več smrtnih primerih, ker jo lahko uporabniki zaužijejo nevede in ker ta snov nima medicinske vrednosti, bi bilo treba za 4,4′-DMAR uvesti nadzorne ukrepe.
Apart from its use in analytical reference materials, and in scientific research investigating its chemistry, pharmacology and toxicology, there is no indication that it is being used for other purposes.
Ker je v treh državah članicah uveden nadzor za 4,4′-DMAR na podlagi nacionalne zakonodaje, ki je usklajena z obveznostmi iz Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971, pet držav članic pa nadzor izvaja z drugimi zakonodajnimi ukrepi, bi uvedba nadzornih ukrepov za to snov po vsej Uniji pripomogla k preprečevanju nastanka ovir v čezmejnem sodelovanju na področju kazenskega pregona in pravosodja ter zagotovila zaščito pred tveganji, ki lahko nastanejo zaradi razpoložljivosti in uporabe te snovi.
The Risk Assessment Report reveals that there is limited scientific evidence available on 4,4′-DMAR and points out that further research would be needed to determine the health and social risks that it poses.
Poročilo o oceni tveganja glede nove psihoaktivne snovi 1-cikloheksil-4-(1,2-difeniletil)piperazin (v nadaljnjem besedilu: MT-45) je bilo pripravljeno v skladu s členom 6(2), (3) in (4) Sklepa 2005/387/PNZ na posebnem zasedanju razširjenega znanstvenega odbora ECSDZD, nato pa je bilo Komisiji in Svetu predloženo 6. oktobra 2014.
However, the evidence and information currently available provides sufficient ground for subjecting 4,4′-DMAR to control measures across the Union.
MT-45 je N,N′-disubstituiran piperazin, ki ima cikloheksanski obroč vezan na enega od dušikovih atomov obroča piperazina, na drug dušikov atom pa je vezan 1,2-difeniletil.
As a result of the risks to health that the consumption of 4,4′-DMAR poses, as documented by its detection in several fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value of this substance, 4,4′-DMAR should be subjected to control measures.
MT-45 je ena od vrste analgetikov 1-(1,2-difeniletil) piperazin, ki je bil izumljen v zgodnjih 70-ih letih prejšnjega stoletja.
Given that three Member States control 4,4′-DMAR under national legislation complying with the obligations of the 1971 United Nations Convention on Psychotropic Substances and five Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would protect against the risks that its availability and use can pose.
MT-45 je na trgu drog v Uniji od oktobra 2013, kjer se prodaja kot „kemikalija za raziskave“, zlasti preko interneta.
A Risk Assessment Report on the new psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) was drawn up in accordance with Article 6(2), (3) and (4) of Decision 2005/387/JHA by a special session of the extended Scientific Committee of the EMCDDA, and was subsequently submitted to the Commission and to the Council on 6 October 2014.
ECSDZD je odkril 12 spletišč internetnih dobaviteljev in trgovcev na drobno, ki prodajajo MT-45, nekateri od njih pa imajo verjetno sedež v Uniji.
MT-45 is an N,N′-disubstituted piperazine, having a cyclohexane ring attached to one of the nitrogen atoms of the piperazine ring and a 1,2-diphenylethyl moiety attached to the other nitrogen atom.
Ista država članica je poročala tudi o približno 18 primerih zastrupitve brez smrtnega izida, klinični znaki pa so bili podobni zastrupitvi z opioidi, ki je bila v nekaterih primerih odzivna na naloksonom, tj. antagonist opioidnih receptorjev.
MT-45 is one of a series of 1-(1,2-diphenylethyl)piperazine analgesics invented in the early 1970s.
Več študij na živalih kaže, da je akutna toksičnost MT-45 nekajkrat večja od morfina.
The EMCDDA has identified 12 sites of internet suppliers and retailers that have offered MT-45 for sale, including some apparently based in the Union.
Zdi se, da ga večinoma uporabljajo osebe, ki si želijo v domačem okolju poskusiti novo snov, ali odvisniki od opioidov, ki nimajo dostopa do heroina ali drugih opioidov.
A total of 28 fatalities occurring between November 2013 and July 2014 have been reported by one Member State.
Lahko se zgodi, da uporabniki mešajo MT-45 z drugimi psihoaktivnimi snovmi.
In most cases, the presence of MT-45 in biological samples was analytically confirmed.
Informacije o socialnih tveganjih, ki so povezana z MT-45, ne obstajajo.
Some 18 non-fatal intoxications have also been reported by the same Member State, the clinical features of which were similar to opioid intoxication, responding in some cases to the opioid receptor antagonist naloxone.
Ni dokazov o vpletenosti organiziranega kriminala v proizvodnjo, distribucijo, trgovino in dobavo MT-45 v Unijo.
There are several studies in animals indicating that the acute toxicity of MT-45 is several-fold higher than that of morphine.
Kemične predhodne sestavine in sintezne poti, uporabljene v proizvodnji MT-45, ki je bil odkrit v državah članicah, niso znane.
Currently available information suggests that MT-45 has not been widely used.
MT-45 ni na seznamu za nadzor na podlagi Enotne konvencije Združenih narodov o mamilih iz leta 1961 ali Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971.
The substance appears to be mostly used in the home environment either by users willing to try a new substance or by opioid dependent users with no access to heroin or any other opioid.
MT-45 nima dokazane ali priznane medicinske ali veterinarske uporabe v Uniji.
Users may combine MT-45 with other psychoactive substances.
Poročilo o oceni tveganja navaja, da je o MT-45 na voljo malo znanstvenih dokazov, in opozarja na potrebo po nadaljnjih raziskavah, da bi se ugotovilo, kakšna zdravstvena in socialna tveganja povzroča ta nova psihoaktivna snov.
There is no information on the social risks that may be related to MT-45.
Vendar je glede na razpoložljive dokaze in informacije dovolj razlogov za uvedbo nadzornih ukrepov za MT-45 po vsej Uniji.
There is no evidence of involvement of organised crime in the manufacture, distribution, trafficking and supply of MT-45 in the Union.
Zaradi tveganj za zdravje, ki jih prinaša ta snov, saj je bila njena prisotnost dokumentirana v več smrtnih primerih, in zaradi pomanjkanja njene medicinske vrednosti, bi bilo treba za MT-45 uvesti nadzorne ukrepe.
The chemical precursors and the synthetic routes used to manufacture the MT-45 detected in Member States are unknown.
Ker je v eni državi članici uveden nadzor za MT-45 na podlagi nacionalne zakonodaje, ki je usklajena z obveznostmi iz Enotne konvencije Združenih narodov o mamilih iz leta 1961 in Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971, sedem držav članic pa nadzor izvaja z drugimi zakonodajnimi ukrepi, bi uvedba nadzornih ukrepov za to snov po vsej Uniji pripomogla k preprečevanju nastanka ovir v čezmejnem sodelovanju na področju kazenskega pregona in pravosodja ter zagotovila zaščito pred tveganji, ki lahko izhajajo iz razpoložljivosti in uporabe te snovi.
MT-45 is not listed for control under the 1961 United Nations Single Convention on Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances.
Sklep 2005/387/PNZ Svetu podeljuje izvedbena pooblastila, da bi se bilo mogoče na ravni Unije z uvedbo nadzornih ukrepov po vsej Uniji za nove psihoaktivne snovi hitro in strokovno odzvati na njihov pojav, ki ga države članice ugotovijo in o njem poročajo.
MT-45 has no established or acknowledged human or veterinary medical use in the Union.
Pogoji za izvrševanje teh izvedbenih pooblastil so bili izpolnjeni in postopki upoštevani, zato bi bilo treba sprejeti izvedbeni sklep za uvedbo nadzornih ukrepov za 4,4′-DMAR in MT-45 v celotni Uniji.
The Risk Assessment Report reveals that there is limited scientific evidence available on MT-45 and points out that further research would be needed to determine the health and social risks that it poses.
Sklep 2005/387/PNZ je za Dansko zavezujoč, zato sodeluje pri sprejetju in uporabi tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ.
However, the evidence and information currently available provides sufficient grounds for subjecting MT-45 to control measures across the Union.
Sklep 2005/387/PNZ je za Irsko zavezujoč, zato sodeluje pri sprejetju in uporabi tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ.
As a result of the health risks that it poses, as documented by its detection in several fatalities, and of the lack of medical value of this substance, MT-45 should be subjected to control measures.
Sklep 2005/387/PNZ ni zavezujoč za Združeno kraljestvo, zato ne sodeluje pri sprejetju tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ in zanj ni zavezujoč niti se v njem ne uporablja –
Given that one Member State controls MT-45 under national legislation complying with the obligations under the 1961 United Nations Single Convention on Narcotic Drugs and under the 1971 United Nations Convention on Psychotropic Substances and seven Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would protect against the risks that its availability and use can pose.
SPREJEL NASLEDNJI SKLEP:
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Člen 1
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 4,4′-DMAR and MT-45 under control across the Union.
Nadzorni ukrepi po vsej Uniji se uvedejo za naslednji novi psihoaktivni snovi:
Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
etil-5-(4-metilfenil)-4,5-dihidrooksazol-2-amin (4,4′-DMAR);
Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
ikloheksil-4-(1,2-difeniletil)piperazin (MT-45).
The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision which implements Decision 2005/387/JHA and is not bound by it or subject to its application,
Člen 2
HAS ADOPTED THIS DECISION:
Države članice do 21. oktobra 2016 sprejmejo potrebne ukrepe v skladu s svojim nacionalnim pravom, da za novi psihoaktivni snovi iz člena 1 uvedejo nadzorne ukrepe in kazenske sankcije, kot jih določa njihova zakonodaja v skladu z obveznostmi iz Enotne konvencije Združenih narodov o mamilih iz leta 1961 in/ali Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971.
The following new psychoactive substances shall be subjected to control measures across the Union:
Ta sklep začne veljati dan po objavi v Uradnem listu Evropske unije.
ethyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR);
Ta sklep se uporablja v skladu s Pogodbama.
yclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45).
V Luxembourgu, 8. oktobra 2015
By 21 October 2016, Member States shall take the necessary measures, in accordance with their national law, to subject the new psychoactive substances referred to in Article 1 to control measures and criminal penalties, as provided for under their legislation complying with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs and/or under the 1971 United Nations Convention on Psychotropic Substances.
Predsednik
Article 3
UL L 127, 20.5.2005, str. 32.
This Decision shall enter into force on the day following that of its publication in the Official Journal of the European Union.
4,4′-DMAR je na trgu drog v Uniji vsaj od decembra 2012 sistemu zgodnjega opozarjanja pa je bil sporočen decembra 2012.
This Decision shall apply in accordance with the Treaties.
Devet držav članic je poročalo o odkritjih ob zasegih snovi, predvsem v obliki belega ali barvnega praška in tablet ter bioloških in zbranih vzorcev.
Done at Luxembourg, 8 October 2015.
Med junijem 2013 in junijem 2014 je bilo v treh državah članicah evidentiranih 31 smrtnih primerov, povezanih s 4,4′-DMAR.
For the Council
V večini primerov je bil 4,4′-DMAR bodisi vzrok smrti bodisi je skupaj z drugimi snovmi verjetno prispeval k smrtnemu izidu.
The President
Ena od držav članic je sporočila, da je bilo zabeleženih 28 smrtnih žrtev med novembrom 2013 in julijem 2014.
OJ L 127, 20.5.2005, p. 32.
V večini primerov je bila prisotnost MT-45 v bioloških vzorcih potrjena z analizo.
Council Implementing Decision (EU) 2015/1874
Izvedbeni sklep Sveta (EU) 2015/1874
A Risk Assessment Report on 4-methylamphetamine was drawn up in accordance with Article 6 of Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and was subsequently received by the Commission on 29 November 2012.
Poročilo o oceni tveganja glede 4-metilamfetamina je bilo pripravljeno v skladu s členom 6 Sklepa 2005/387/PNZ na posebnem zasedanju razširjenega znanstvenega odbora Evropskega centra za spremljanje drog in zasvojenosti z drogami (EMCDDA) ter nato predloženo Komisiji 29. novembra 2012.
The specific physical effects of 4-methylamphetamine have been rarely reported by users, since users are typically unaware that they have taken the substance.
Uporabniki 4-metilamfetamina redko navajajo njegove posebne fizične učinke, saj običajno ne vedo, da so zaužili to snov.
Limited data available relating to humans suggest that the adverse effects of 4-methylamphetamine include hyperthermia, hypertension, anorexia, nausea, perspiration, gastric distress, coughing, vomiting, headache, palpitations, insomnia, paranoia, anxiety and depression.
Omejeni dostopni podatki, ki se nanašajo na ljudi, kažejo, da škodljivi učinki 4-metilamfetamina vključujejo hipertermijo, povišan krvni tlak, anoreksijo, slabost, znojenje, želodčne težave, kašelj, bruhanje, glavobol, palpitacije, nespečnost, paranojo, tesnobo in depresijo.
Certain evidence suggests that a combination of 4-methylamphetamine with other substances, including amphetamine and caffeine, may result in a higher risk of overall enhanced toxicity.
Po nekaterih podatkih bi lahko za 4-metilamfetamin v kombinaciji z drugimi snovmi, kot sta amfetamin in kofein, obstajalo tveganje splošne toksičnosti.
While it is not possible to determine with certainty from the information available the role of 4-methylamphetamine in those fatalities, in some cases the substance was the predominant drug detected, with levels comparable to those found in certain cases of death caused by the consumption of amphetamine.
Čeprav glede na dostopne informacije ni mogoče z gotovostjo določiti vloge 4-metilamfetamina v teh smrtnih primerih, je bila ta snov v nekaterih primerih prevladujoča ugotovljena droga, ugotovljene ravni pa so bile primerljive s tistimi, ki so bile ugotovljene v nekaterih smrtnih primerih zaradi zaužitja amfetamina.
ethylamphetamine is not currently under assessment and has not been under assessment by the United Nations' system.
etilamfetamin ni v postopku ocenjevanja in ni bil ocenjen v okviru sistema Združenih narodov.
Two other Member States apply the generic definition of phenethylamine in their national legislation to the substance, while one Member State controls it under its medicines legislation.
Vendar je glede na razpoložljive dokaze dovolj razlogov za uvedbo nadzornih ukrepov za 4-metilamfetamin po vsej Uniji.
The Risk Assessment Report reveals that there is limited scientific evidence available on the characteristics and risks of 4-methylamphetamine and points out that further studies are required on the overall health and social risks associated with the substance.
Zaradi zdravstvenih tveganj zaradi 4-metilamfetamina, kot so bila dokumentirana ob ugotovitvi njegove prisotnosti pri več zabeleženih smrtnih primerih, zlasti kadar se uporablja v kombinaciji z drugimi snovmi, zaradi njegove velike podobnosti z amfetaminom po videzu in učinkih, zaradi možnosti, da ga uporabniki zaužijejo nevede in zaradi njegove omejene medicinske vrednosti ali uporabe, bi bilo treba za 4-metilamfetamin uvesti nadzorne ukrepe v vsej Uniji.
However, the evidence available provides sufficient grounds for subjecting 4-methylamphetamine to control measures across the Union.
Ker je deset držav članic že uvedlo nadzorne ukrepe za 4-metilamfetamin, bi lahko z uvedbo nadzornih ukrepov v vsej Uniji pripomogli k odpravljanju težav pri čezmejnem kazenskem pregonu in sodelovanju pravosodnih organov.
As a result of the health risks it poses, as documented by its detection in several reported fatalities, especially when used in combination with other substances, of its strong resemblance in terms of appearance and effects with amphetamine, of the fact that users may unknowingly consume the substance, and of its limited medical value or use, 4-methylamphetamine should be subjected to control measures across the Union.
Nadzorni ukrepi v vsej Uniji lahko pomagajo preprečevati razvoj 4-metilamfetamina kot nadomestka amfetamina na nezakonitem trgu z drogami.
Given that 10 Member States already control 4-methylamphetamine, subjecting it to control measures across the Union may help avoid problems in cross-border law enforcement and judicial cooperation.
Sklep 2005/387/PNZ Svetu podeljuje izvedbena pooblastila, da bi se bilo mogoče na ravni Unije z uvedbo nadzornih ukrepov po vsej Uniji za nove psihoaktivne snovi hitro in strokovno odzvati na njihov pojav, ki ga države članice ugotovijo in o njem poročajo.
Union-wide control measures may also help prevent 4-methylamphetamine developing as an alternative to amphetamine in the illicit drug markets.
Pogoji za izvrševanje teh izvedbenih pooblastil so bili izpolnjeni in postopki upoštevani, zato bi bilo treba sprejeti izvedbeni sklep za uvedbo nadzornih ukrepov za 4-metilamfetamina v vsej Uniji.